iCLATCH I // Clinical aspects of itch
Characterization and comparison of pruritus characteristics and burden of chronic pruritus in different pruritic skin disorders
iCLATCH II // Clinical aspects of itch
Characterization of different patterns of pruritus provoked by different itch inducing substances
iCHIP // Itch in psoriasis
Define prevalence and impact of itch in psoriasis patients and prepare for further studies aiming at defining biomarkers of itch in psoriasis
iCholUQoL // Quality of Life in Cholinergic Urticaria
Development of a tool to study the burden of CholU and to follow the changes of Quality of Life during therapy
CRIPS // Cromoglicate in Psoriasis
Evaluate the efficacy of cromoglicate cream compared to cream vehicle in the treatment of itch in psoriasis
iEMMA // Effects of p38-MAP Kinase-inhibitor on Mast cell activation
Investigate the anti-inflammatory effect of a p38 MAPKinase inhibitor (EO1606) in contact eczema or mast cell driven inflammation
iETOP // Effects of topical propranolol on itch
Investigate the anti-pruritic and anti-inflammatory effect of a topical beta-adrenergic antagonist (propranolol)
iVEGF (iETOK) // Potential for effects of topical administration of multi-kinase inhibitor LEO27989
Evaluating effects of the multikinase inhibitor LEO27989 and propranolol on phosphorylation of VEGFR2
PCT // Prurigo Control Test
Develop and validate a clinical score for prurigo (including prurigo nodularis [PN] and prurigo simplex[PS]), to define neuropathology in prurigo, to detect impairment in pain vs. itch sensitivity, and to identify histologic and serum biomarker
iTAPP // Topical aprepitant in prurigo patients
Investigate the efficacy and safety of topical treatment with aprepitant gel (10 mg/g gel) on pruritus compared to placebo, after 4 weeks of treatment in prurigo patients.